Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Large Cap

Large Cap

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Individualized Cancer Treatment: Merck/Moderna’s Personalized Skin Cancer Therapy Enters Late-Stage Of Development

By Vandana Singh
July 26, 12:04 PM
Merck & Co Inc (NYSE: MRK) and Moderna Inc (NASDAQ: MRNA) initiated a pivotal Phase 3 randomized V940-001 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in

MRK

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

Novo Nordisk’s Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports

By Vandana Singh
July 26, 11:07 AM
The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss product sold by Novo Nordisk A/S (NYSE: NVO).

AZN

Read More
1 minute read
  • Earnings
  • Equities
  • Guidance
  • Large Cap
  • Markets
  • News

Hess Surpasses Q2 Estimates, Raises FY23 Production Outlook

By Lekha Gupta
July 26, 10:55 AM
Hess Corp (NYSE: HES) reported Q2 revenues of $2.32 billion, beating the 

HES

Read More
1 minute read
  • Earnings
  • Equities
  • Guidance
  • Large Cap
  • Markets
  • News

Fortive Q2: 4.3% Sales Growth, Earnings Beat & More

By Lekha Gupta
July 26, 10:48 AM
Fortive Corp (NYSE: FTV) reported Q2 2023 sales growth of 4.3% Y/Y to $1.53 billion, beating the 

FTV

Read More
1 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • Large Cap
  • News

Novo Nordisk’s Obesity Drug Saxenda Not Included In WHO’s Essential Drug List

By Vandana Singh
July 26, 10:24 AM
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

MKGAF

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook

By Vandana Singh
July 26, 10:21 AM
Quest Diagnostics Inc (NYSE: DGX) posted Q2 FY23 adjusted EPS of $2.30, down 2.5% Y/Y, beating the consensus of $2.27.

DGX

Read More
1 minute read
  • Equities
  • Guidance
  • Large Cap
  • Markets
  • Movers
  • News
  • Small Cap

Why SunPower Shares Are Diving Today

By Lekha Gupta
July 26, 9:52 AM
SunPower Corp (NASDAQ: SPWR) shares are trading lower by around 15% after the company reported below-consensus Q2 revenues and 

SPWR

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

GSK Says ‘Excellent’ Q2 Performance Boosted By Vaccine & HIV Drug Sales, Raises 2023 Outlook

By Vandana Singh
July 26, 9:36 AM
GSK plc (NYSE: GSK) reported Q2 FY23 sales of £7.18 billion ($8.97 billion), up 4% Y/Y on t

GSK

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

Thermo Fisher Below Street Expectation, Lowers Annual Guidance Citing ‘Macroeconomic Environment’

By Vandana Singh
July 26, 9:27 AM
Thermo Fisher Scientific Inc (NYSE: TMO) has posted Q2 revenue of $10.69 billion, down 3% Y/Y, missing the 

TMO

Read More
2 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • Large Cap
  • News
  • Regulations

Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries

By Vandana Singh
July 26, 9:06 AM
Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling 

ABBV

Posts pagination

Previous 1 … 253 254 255 … 437 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service